^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MELTF expression

    i
    Other names: MELTF, Melanotransferrin, MAP97, CD228, MTF1, MFI2, MTf, Antigen P97 (Melanoma Associated) Identified By Monoclonal Antibodies 133.2 And 96.5, Membrane-Bound Transferrin-Like Protein, FLJ38863, MGC4856, Melanoma-Associated Antigen P97, CD228 Antigen
    Entrez ID:
    4241
    Related biomarkers:
    Expression
    5ms
    The E2F1/MELTF axis fosters the progression of lung adenocarcinoma by regulating the Notch signaling pathway. (PubMed, Mutat Res)
    Together, our outcomes demonstrated that E2F1 fostered LUAD progression by activating MELTF via the Notch signaling activity. Hence, MELTF emerged as a feasible target for treating LUAD.
    Journal
    |
    NOTCH1 (Notch 1) • MELTF (Melanotransferrin) • HES1 • E2F1 (E2F transcription factor 1)
    |
    NOTCH1 expression • MELTF expression • MFI2 expression
    |
    RG4733
    1year
    SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models. (PubMed, Mol Cancer Ther)
    Overall, SGN-CD228A is a CD228-directed, investigational ADC that employs innovative technology and has compelling preclinical antitumor activity. SGN-CD228A is being investigated in an ongoing Phase I clinical trial (NCT04042480) in patients with advanced solid tumors.
    Preclinical • Journal
    |
    MELTF (Melanotransferrin)
    |
    MELTF expression • MFI2 expression
    |
    SGN-CD228A
    1year
    SGN-BB228, a CD228-directed costimulatory antibody anticalin® bispecific provides potent and conditional 4-1BB costimulation to T cells in vivo and in an in vitro model of T cell exhaustion (AACR 2023)
    Interestingly, in this system, anti-PD-1 (nivolumab) failed to reinvigorate functionally exhausted T cells despite high PD-L1 expression by tumor cells. Together these data highlight SGN-BB228, a first-in-class, investigational CD228 x 4-1BB costimulatory Antibody Anticalin® bispecific with potent and CD228-conditional 4-1BB costimulatory activity with therapeutic potential in multiple solid tumor types. These data support the first-in-human phase 1 clinical trial of SGN-BB228 in advanced melanoma and other solid tumors (NCT05571839), which is currently recruiting.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • MELTF (Melanotransferrin)
    |
    PD-L1 expression • PD-L1 overexpression • MELTF expression • MFI2 expression
    |
    Opdivo (nivolumab) • PF-08046049